Page 62 - GTM-4-1

Global Translational Medicine Incretins and cardiorenal disease

20. Jakubowska A, Roux CW, Viljoen A. The road towards agonist. JCI Insight. 2020;5(17):e140532.
triple agonists: Glucagon-like peptide 1, glucose-dependent doi: 10.1172/jci.insight.140532
insulinotropic polypeptide and glucagon receptor-an
update. Endocrinol Metab (Seoul). 2024;39(1):12-22. 31. Zeitler P, Galindo RJ, Davies MJ, et al. Early-onset type 2
diabetes and tirzepatide treatment: A post hoc analysis
doi: 10.3803/EnM.2024.1942
from the SURPASS clinical trial program. Diabetes Care.
21. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for 2024;47(6):1056-1064.
metabolic dysfunction-associated steatohepatitis with liver doi: 10.2337/dc23-2356
fibrosis. N Engl J Med. 2024;391:299-310.
32. Malhotra A, Bednarik J, Chakladar S, et al. Tirzepatide for
doi: 10.1056/NEJMoa2401943
the treatment of obstructive sleep apnea: Rationale, design,
22. Abdelmalek MF, Suzuki A, Sanchez W, et al. A phase 2, and sample baseline characteristics of the SURMOUNT-
adaptive randomized, double-blind, placebo-controlled, OSA phase 3 trial. Contemp Clin Trials. 2024;141:107516.
multicenter, 52-week study of HM15211 in patients with doi: 10.1016/j.cct.2024.107516
biopsy-confirmed non-alcoholic steatohepatitis-study
design and rationale of HM-TRIA-201 study. Contemp Clin 33. ClinicalTrials.gov Identifier: NCT04255433. A Study of
Trials. 2023;130:107176. Tirzepatide (LY3298176) Compared with Dulaglutide on
Major Cardiovascular Events in Participants with Type
doi: 10.1016/j.cct.2023.107176
2 Diabetes (SURPASS-CVOT). Available from: https://
23. Nauck MA, Müller TD. Incretin hormones and type 2 clinicaltrials.gov/study/nct04255433 [Last accessed on 2024
diabetes. Diabetologia. 2023;66(10):1780-1795. Jun 10].
doi: 10.1007/s00125-023-05956-x 34. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-
receptor agonist retatrutide for obesity: A phase 2 trial. N
24. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor
agonists in the treatment of type 2 diabetes-state-of-the-art. Engl J Med. 2023;389:514-526.
Mol Metab. 2021;46:101102. doi: 10.1056/NEJMoa2301972
doi: 10.1016/j.molmet.2020.101102 35. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP,
GLP-1 and glucagon receptor agonist, for people with type
25. Tschöp M, Nogueiras R, Ahrén B. Gut hormone-
based pharmacology: Novel formulations and future 2 diabetes: A randomised, double-blind, placebo and active-
possibilities for metabolic disease therapy. Diabetologia. controlled, parallel-group, phase 2 trial conducted in the
2023;66(10):1796-1808. USA. Lancet. 2023;402(10401):529-544.
doi: 10.1016/S0140-6736(23)01053-X
doi: 10.1007/s00125-023-05929-0
36. Jensen TL, Brønden A, Karstoft K, Sonne DP,
26. Mann JFE, Rossing P, Bakris G, et al. Effects of semaglutide
with and without concomitant SGLT2 inhibitor use in Christensen MB. The body weight reducing effects of
participants with type 2 diabetes and chronic kidney disease tirzepatide in people with and without type 2 diabetes:
in the flow trial. Nat Med. 2024;30:2849-2856. A review on efficacy and adverse effects. Patient Prefer
Adherence. 2024;18:373-382.
doi: 10.1038/s41591-024-03133-0
doi: 10.2147/PPA.S419304
27. Moiz A, Levett JY, Filion KB, Peri K, Reynier P, Eisenberg MJ.
Long-term efficacy and safety of once-weekly semaglutide 37. Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is
for weight loss in patients without diabetes: A systematic the pipeline for future medications for obesity? Int J Obes
review and meta-analysis of randomized controlled trials. (Lond). 2024.
Am J Cardiol. 2024;222:121-130. doi:10.1038/s41366-024-01473-y
doi: 10.1016/j.amjcard.2024.04.041 38. Locatelli JC, Costa JG, Haynes A, et al. Incretin-based
weight loss pharmacotherapy: Can resistance exercise
28. Teva Launches Generic Formulation of Liraglutide in US.
Available from: https://www.pharmacytimes.com/view/ optimize changes in body composition? Diabetes Care.
teva-launches-generic-formulation-of-liraglutide-in-us 2024:dci230100.
[Last accessed on 2024 Jun 28]. doi: 10.2337/dci23-0100
29. Scheen AJ. Dual GIP/GLP-1 receptor agonists: New 39. Conte C, Hall KD, Klein S. Is weight loss-induced muscle
advances for treating type-2 diabetes. Ann Endocrinol mass loss clinically relevant? JAMA. 2024;332(1):9-10.
(Paris). 2023;84(2):316-321.
doi: 10.1001/jama.2024.6586
doi: 10.1016/j.ando.2022.12.423
40. Pillai P, Modarressi T. GLP1RAs in Clinical Practice:
30. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is Therapeutic Advances and Safety Perspectives; 2024. American
an imbalanced and biased dual GIP and GLP-1 receptor College of Cardiology. Available from: https://www.acc.org/

Volume 4 Issue 1 (2025) 54 doi: 10.36922/gtm.4405